Sugi Predict

Sugi Predict / Compounds / SCHEMBL3417815

SCHEMBL3417815

SCHEMBL3417815

CCCCC(N=C=O)C(=O)OCC

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 4/20 0.38
▸ CA1 P00915 2/20 0.38
▸ TSHR P16473 2/20 0.34
▸ TDP1 Q9NUW8 2/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ ATM Q13315 1/20 0.34
▸ POLB P06746 2/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ CPB2 Q96IY4 1/20 0.33
▸ ZDHHC7 Q9NXF8 1/20 0.33
▸ ALDH1A1 P00352 3/20 0.32
▸ KMT2A Q03164 3/20 0.32
▸ MAPT P10636 1/20 0.32
▸ LMNA P02545 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11260897 0.93 ZDHHC7 (0.41) CA2CPB2ZDHHC7MAPT
SCHEMBL11455381 0.93 ZDHHC7 (0.41) CA2CPB2ZDHHC7MAPT
SCHEMBL10451644 0.88 ALDH1A1 (0.42) CA2CA1TSHRTDP1CYP3A4
SCHEMBL10451509 0.86 CA2 (0.50) CA2CA1TSHRTDP1CYP3A4
SCHEMBL4907463 0.86 CA2 (0.50) CA2CA1TSHRTDP1CYP3A4
SCHEMBL20361871 0.86 CA2 (0.50) CA2CA1TSHRTDP1CYP3A4
SCHEMBL11246028 0.85 CPB2 (0.30) CPB2
SCHEMBL23794918 0.83 CPB2 (0.33) CPB2
SCHEMBL10451486 0.83 L3MBTL1 (0.37) CA2CA1TSHRTDP1CYP3A4
SCHEMBL10449702 0.83 CA2 (0.38) CA2CA1TSHRTDP1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227414-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2023-07-20 — — US disclosed
US-11643397-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2023-05-09 — — US disclosed
US-20210347740-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2021-11-11 — — US disclosed
US-20200157055-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2020-05-21 — — US disclosed
CN-110465468-A The method for forming multilayer film KANSAI PAINT CO LTD 2019-11-19 — — CN disclosed
CN-110325563-A Polymer composition and its manufacturing method containing modified chlorinated polyolefin 关西涂料株式会社 2019-10-11 — — CN disclosed
CN-110167734-A MOLDED ARTICLE AND METHOD FOR PRODUCING SAME 住友化学株式会社 2019-08-23 — — CN disclosed
US-10336711-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2019-07-02 — — US disclosed
US-20180305323-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2018-10-25 — — US disclosed
US-10035779-B2 Prolyl hydroxylase inhibitors GlaxoSmithKline, LLC (US) 2018-07-31 — — US disclosed
CN-102471588-A Antistatic resin composition SANYO CHEMICAL IND LTD 2012-05-23 — — CN disclosed
CN-101896521-A Water-based paint compositions KANSAI PAINT CO LTD 2010-11-24 — — CN disclosed
US-20100113444-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-05-06 — — US disclosed
US-20090240004-A1 FUNCTIONALIZED POLYURETHANE RESIN, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF CONSTRUCTION RESEARCH & TECHNOLOGY GMBH (DE) 2009-09-24 — — US disclosed
EP-2037922-A2 PROLYL HYDROXYLASE INHIBITORS SmithKline Beecham Corporation (US) 2009-03-25 — — EP disclosed
CN-100415806-C Block polymer and antistatic agent comprising the same SANYO CHEMICAL IND LTD (JP) 2008-09-03 — — CN disclosed
WO-2007150011-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-12-27 — — WO disclosed
CN-1827670-A Block polymer and antistatic agent comprising the same SANYO CHEMICAL IND LTD (JP) 2006-09-06 — — CN disclosed
CN-1246366-C Block polymer and antistatic agent comprising the same SANYO CHEMICAL IND LTD (JP) 2006-03-22 — — CN disclosed
CN-1346379-A Block polymer and antistatic agent comprising the same SANYO CHEMIAL IND LTD (JP) 2002-04-24 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11643397-B2 Prolyl hydroxylase inhibitors HIF1AN, EGLN3, EGLN2 CA2 1387/4885CA1 3291/4885TSHR 2722/4885
US-20210347740-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 CA2 1387/4885CA1 3291/4885TSHR 2722/4885
US-20100113444-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN3, EGLN2 CA2 1534/4885CA1 3353/4885TSHR 2718/4885
US-10336711-B2 Prolyl hydroxylase inhibitors HIF1AN, EGLN3, EGLN2 CA2 1387/4885CA1 3291/4885TSHR 2722/4885
US-20200157055-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 CA2 1387/4885CA1 3291/4885TSHR 2722/4885
US-20180305323-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 CA2 1387/4885CA1 3291/4885TSHR 2722/4885
US-10035779-B2 Prolyl hydroxylase inhibitors HIF1AN, EGLN3, EGLN2 CA2 1387/4885CA1 3291/4885TSHR 2722/4885
US-20230227414-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 CA2 1387/4885CA1 3291/4885TSHR 2722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.